{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:15:44Z","timestamp":1749701744010,"version":"3.41.0"},"reference-count":2,"publisher":"Massachusetts Medical Society","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2022,10,20]]},"DOI":"10.1056\/nejmc2211125","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T21:01:28Z","timestamp":1666213288000},"page":"1527-1528","source":"Crossref","is-referenced-by-count":2,"title":["Brentuximab Vedotin in Advanced Hodgkin\u2019s Lymphoma"],"prefix":"10.1056","volume":"387","member":"150","reference":[{"key":"e_1_2_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_3_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01777"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2211125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:10:30Z","timestamp":1749683430000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2211125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":2,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,10,20]]}},"alternative-id":["10.1056\/NEJMc2211125"],"URL":"https:\/\/doi.org\/10.1056\/nejmc2211125","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"type":"print","value":"0028-4793"},{"type":"electronic","value":"1533-4406"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}